Last news
Gen Zers turn their minds to education and its future

Gen Zers turn their minds to education and its future

...

HORP ANNOUNCES 2023 BREAK THE CEILING TOUCH THE SKY® LIST OF THE AMERICAS' MOST INSPIRATIONAL WOMEN IN LEADERSHIP

HORP ANNOUNCES 2023 BREAK THE CEILING TOUCH THE SKY® LIST OF THE AMERICAS' MOST INSPIRATIONAL WOMEN IN LEADERSHIP

...

Color Star Enters Into a Strategic Cooperation Agreement with Quality Plus To Join Forces in Marketing Efforts

Color Star Enters Into a Strategic Cooperation Agreement with Quality Plus To Join Forces in Marketing Efforts

...

Syntach AB announces €17.5M in Blended Funding, Names Patrick NJ Schnegelsberg as New CEO, and Appoints Cansel Isikli as VP of RA/Q

Syntach AB announces €17.5M in Blended Funding, Names Patrick NJ Schnegelsberg as New CEO, and Appoints Cansel Isikli as VP of RA/Q

...

CPP Investments Anchors New IndoSpace Fund with US$205 Million Investment

CPP Investments Anchors New IndoSpace Fund with US$205 Million Investment

...

DELHIWOOD 2023 - HERALDING A NEW ERA FOR THE INDIAN WOODWORKING AND FURNITURE MANUFACTURING INDUSTRY

DELHIWOOD 2023 - HERALDING A NEW ERA FOR THE INDIAN WOODWORKING AND FURNITURE MANUFACTURING INDUSTRY

...

Ungerboeck Unveils New Brand Identity and Announces Name Change to Momentus Technologies

Ungerboeck Unveils New Brand Identity and Announces Name Change to Momentus Technologies

...

Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

...

menu
menu